Tissue and Metabolomic Biomarkers of Recurrent Renal Cell Carcinoma
Abstract
The purpose of the study was to harness cutting-edge metabolomic and proteomic biomarker discovery technologies to identify novel biomarkers for ccRCC aggressiveness in primary tumor samples excised during surgery. Fresh-frozen tissue samples from 25 intermediate risk ccRCC patients who experienced progression to metastasis within 3 years of surgery and 25 intermediate risk ccRCC patients who remain progression free after 5 years of follow-up were be evaluated by MALDI mass spectrometry based tissue imaging and metabolomic profiling at Metabolon, Inc. This data has also been extended using new analysis workflows developed at MUSC using the high resolution MALDI-FTICR instrument to analyze lipid and glycan species directly on tissue. An emphasis on examining the molecular changes at the tumor margin interface has also been implemented. These latter methods are currently unique to MUSC and were developed specifically for this project. The cumulative data is currently being analyzed with the clinical data in the partnering PIs facility.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2013
- Accession Number
- ADA592797
Entities
People
- Alexander Parker
- Richard R. Drake
Organizations
- Medical University of South Carolina